DRI Healthcare Trust

Equities

DHT.U

CA23344H1091

Pharmaceuticals

Market Closed - Toronto S.E. 04:00:00 2024-03-28 pm EDT 5-day change 1st Jan Change
15.87 CAD -1.67% Intraday chart for DRI Healthcare Trust +0.57% +27.16%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
DRI Healthcare Trust Seeks Acquisitions CI
Transcript : DRI Healthcare Trust, Q4 2023 Earnings Call, Feb 29, 2024
DRI Healthcare Trust Reports Earnings Results for the Full Year Ended December 31, 2023 CI
DRI Healthcare Trust Declares Quarterly Cash Distribution for the First Quarter of 2024, Payable on April 19, 2024 CI
DRI Healthcare Trust Brief: Announcing 2024 royalty income guidance of US$153 to US$155 million, excluding milestone income and any new transactions MT
DRI Healthcare Trust Brief: Q4 Net Earnings per Unit of US$0.39 (basic and diluted; Increasing quarterly cash distribution MT
DRI Healthcare Trust Reports Earnings Results for the Fourth Quarter Ended December 31, 2023 CI
Tranche Update on DRI Healthcare Trust (TSX:DHT.UN)'s Equity Buyback Plan announced on November 13, 2023. CI
National Bank Raises DRI Healthcare Target to $22 on Omidria News, Guidance Increase MT
DRI Healthcare Trust Expands Royalty Entitlement on US Net Sales of Omidria, Updates Deployment and CAGR Guidance MT
DRI Healthcare Trust Brief: Announcing Expansion of its Royalty Entitlement on the US Net Sales of Omidria), Updating Deployment and CAGR Guidance MT
National Bank Highlights Key Takeaways From DRI Healthcare Trust's Investor Meetings; Raises Price Target MT
DRI Healthcare Trust Brief: Says This special cash distribution is in addition to quarterly cash distribution declared on November 13, 2023 of US$0.075 per trust unit MT
DRI Healthcare Trust Brief: Special cash distribution will be made payable to unitholders of record at close of business on December 31, 2023, and paid to such unitholders on January 19, 2024 MT
DRI Healthcare Trust Brief: Declaring a special cash distribution in the amount of US$0.2662 per trust unit MT
DRI Healthcare Trust Declares Special Distribution, Payable on January 19, 2024 CI
Transcript : DRI Healthcare Trust, Q3 2023 Earnings Call, Nov 14, 2023
DRI Healthcare Trust Swings to a Loss in the Third Quarter MT
DRI Healthcare Trust Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023 CI
DRI Healthcare Trust's Equity Buyback announced on November 7, 2022, has closed with 11,236,113 shares, for $6.57 million. CI
Tranche Update on DRI Healthcare Trust (TSX:DHT.UN)'s Equity Buyback Plan announced on November 7, 2022. CI
Tranche Update on DRI Healthcare Trust (TSX:DHT.UN)'s Equity Buyback Plan announced on November 7, 2022. CI
DRI Healthcare Trust (TSX:DHT.UN) announces an Equity Buyback for 3,280,195 shares, representing 5.82% of its issued share capital. CI
DRI Healthcare Trust authorizes a Buyback Plan. CI
DRI Healthcare Trust Announces Upsized $500 Million Credit Facilities CI
Chart DRI Healthcare Trust
More charts
DRI Healthcare Trust is a Canada-based company, which is engaged in providing financing to advance innovation in the life sciences industry. The Company is involved in pharmaceutical royalty monetization and provides capital to inventors, academic institutions and biopharma companies. It is acquiring approximately 70 royalties on 40-plus drugs, including Eylea, Spinraza, Zytiga, Remicade, Keytruda and Stelara. The Company’s portfolio includes Empaveli, Eylea, Natpara, Omidria, Rydapt, Simponi, Syfovre, Vonjo, Zejula and Zytiga. Its therapeutic areas include influenza, endocrinology, ophthalmology, dermatology, oncology, neurology, autoimmune diseases, heme-onc, lysosomal storage disorder, respiratory diseases, oncology and others. The Company is managed by DRI Capital Inc. Its products are marketed by pharmaceutical companies, including Regeneron, Bayer, Santen; AstraZeneca; Takeda; Galderma Laboratories; Novartis; Biogen; CTI Biopharma; Roche, Novartis, Johnson & Johnson, and others.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
11.73 USD
Average target price
15.16 USD
Spread / Average Target
+29.26%
Consensus
  1. Stock
  2. Equities
  3. Stock DRI Healthcare Trust - Toronto S.E.
  4. News DRI Healthcare Trust
  5. DRI Healthcare Trust Acquires Royalty Interest in Global Sales of Xenpozyme for Treatment of Niemann-Pick Disease